Clinical Trial Update: The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for Lucentis (ranibizumab) in uveitic cystoid macular edema; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Steroid-induced Glaucoma - Borderline
• Uveitis-related Cystoid Macular Edema

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Moorfields Eye Hospital NHS Foundation Trust | Conditions: Uveitis Related Cystoid Macular Edema, Steroid-induced Glaucoma - Borderline | Phase 2 | Status: COMPLETED